– USA, CA – Leading BioSciences, Inc. (LBS), a development stage pharmaceutical company focused on novel treatments in the critical care of acute shock and Multiple Organ Failure (MOF), today announced that Robin M. Jackman, Ph.D., has been named Chief Executive Officer. Dr. Jackman succeeds Dr. Stephen Flaim, who was serving as interim CEO and now returns to his post as company Chairman. LBS additionally announced the appointment of Dr. Tom Hallam as Vice President, Therapeutic Development.
“Leading BioSciences is advancing a revolutionary platform whose initial focus is the treatment and prevention of Multiple Organ Failure, a condition most commonly associated with severe sepsis,” said Dr. Flaim. “We are delighted that Dr. Jackman has joined Leading BioSciences with his proven and successful track record as an early-stage biotech executive. With the additions of both Robin and Tom, we have the right team to advance our lead therapeutic LB1148 into Phase 2 clinical studies both nationally and internationally.”
A 20-year biopharmaceutical industry veteran, Robin was most recently President and CEO of Zacharon Pharmaceuticals where he successfully led the venture-backed startup from financing through new orphan drug program development, multiple new partnerships, and on to a sale of the company last year to BioMarin Pharmaceuticals. Previously Dr. Jackman was Senior Vice President at Vical where he ran the oncology division, which included completing a first-in-human exploratory Phase 1 clinical study, as well as launching and enrolling a Phase 3 worldwide registration clinical trial encompassing over 120 clinical sites in 15 countries. Early in his career he was an investment banker with the life-science unit at BankAmerica Robertson Stephens where he provided strategic and financing services to companies ranging from small venture-backed startups to large multinational pharmaceuticals. Robin holds graduate degrees from Harvard Medical School and Harvard University, and an undergraduate degree from Stanford University.
“Leading BioSciences is developing a remarkable platform with novel and fundamental insights into the underlying mechanisms of several serious conditions,” stated Dr. Jackman. With the promise of our early clinical data, I am looking forward to advancing our treatment for MOF into an efficacy study in these critically ill patients with severe sepsis and septic shock.”
About Leading BioSciences, Inc.
Leading BioSciences is a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of Multiple Organ Failure (MOF) as a result of severe sepsis and shock, a condition with a high mortality rate and very few therapeutic options. The Company’s lead technology is LB1148, a therapy designed to prevent the onset of shock and MOF via the direct administration of a proprietary cocktail into the stomach and lumen of the intestine. Pre-clinical research demonstrated that under conditions of shock, digestive enzymes permeate the wall of the intestine and enter the bloodstream, leading to multi-organ failure and death. LB1148 is the lead product of a new platform “Autodigestion”. Autodigestion is the process by which the body begins to digest itself as digestive enzymes permeate the wall of the small intestine. Autodigestion impacts several different disease states. Complementing LB1148, the Company is developing a companion diagnostic technology, AnaZyme, that uses either breath or blood samples to measure the presence and severity of autodigestion due to shock, and InflammaGen Lavage, a therapeutic for use in open wounds and areas of infection in the peritoneal cavity.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
